The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors
Authors:
- Eric J. LawitzELEric J. Lawitz
- 1 August 2011
- journal article
- review article
- Published by Elsevier in Clinics in Liver Disease
- Vol. 15 (3) , 611-626
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- 61 ONCE DAILY PSI-7977 PLUS PEGIFN/RBV IN A PHASE 2B TRIAL: RAPID VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE PATIENTS WITH HCV GT2/GT3Journal of Hepatology, 2011
- Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of CareViruses, 2010
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Antiviral resistance and hepatitis B therapy #Hepatology, 2009
- Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy #Hepatology, 2009
- DarunavirDrugs, 2009
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsHepatology, 2008
- Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase InhibitorsJournal of Virology, 2007
- Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor TelaprevirGastroenterology, 2007